Re­genxbio, UPenn file patent suit against Sarep­ta re­lat­ed to new Duchenne gene ther­a­py

Re­genxbio, a Rockville, MD-based biotech, and the Uni­ver­si­ty of Penn­syl­va­nia sued Sarep­ta Ther­a­peu­tics for the sec­ond time, this time al­leg­ing patent in­fringe­ment for the com­pa­ny’s new­ly ap­proved gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy.

The suit, filed last week in US Dis­trict Court in the dis­trict of Delaware, al­leges that Sarep­ta and Catal­ent, which man­u­fac­tures Sarep­ta’s gene ther­a­pies, vi­o­lat­ed a patent for Ele­v­idys, the brand name of Sarep­ta’s Duchenne treat­ment that re­ceived FDA ap­proval last week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER